KR20200118233A - 조효소 q10을 이용한 고형 종양의 치료 - Google Patents

조효소 q10을 이용한 고형 종양의 치료 Download PDF

Info

Publication number
KR20200118233A
KR20200118233A KR1020207028370A KR20207028370A KR20200118233A KR 20200118233 A KR20200118233 A KR 20200118233A KR 1020207028370 A KR1020207028370 A KR 1020207028370A KR 20207028370 A KR20207028370 A KR 20207028370A KR 20200118233 A KR20200118233 A KR 20200118233A
Authority
KR
South Korea
Prior art keywords
cancer
coq10
dose
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207028370A
Other languages
English (en)
Korean (ko)
Inventor
니븐 라진 나레인
존 패트릭 맥쿡
폴 와이. 송
Original Assignee
버그 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버그 엘엘씨 filed Critical 버그 엘엘씨
Publication of KR20200118233A publication Critical patent/KR20200118233A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020207028370A 2012-06-01 2013-05-31 조효소 q10을 이용한 고형 종양의 치료 Ceased KR20200118233A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654245P 2012-06-01 2012-06-01
US61/654,245 2012-06-01
PCT/US2013/043785 WO2013181639A1 (en) 2012-06-01 2013-05-31 Treatment of solid tumors using coenzyme q10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147037100A Division KR102163948B1 (ko) 2012-06-01 2013-05-31 조효소 q10을 이용한 고형 종양의 치료

Publications (1)

Publication Number Publication Date
KR20200118233A true KR20200118233A (ko) 2020-10-14

Family

ID=49673946

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207028370A Ceased KR20200118233A (ko) 2012-06-01 2013-05-31 조효소 q10을 이용한 고형 종양의 치료
KR1020147037100A Active KR102163948B1 (ko) 2012-06-01 2013-05-31 조효소 q10을 이용한 고형 종양의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147037100A Active KR102163948B1 (ko) 2012-06-01 2013-05-31 조효소 q10을 이용한 고형 종양의 치료

Country Status (16)

Country Link
US (3) US20140017317A1 (https=)
EP (1) EP2854528B8 (https=)
JP (3) JP6352905B2 (https=)
KR (2) KR20200118233A (https=)
CN (1) CN104507308A (https=)
AU (2) AU2013267166A1 (https=)
BR (1) BR112014029954A2 (https=)
CA (2) CA3090268A1 (https=)
EA (1) EA032345B1 (https=)
ES (1) ES2761449T3 (https=)
IL (1) IL236008B (https=)
IN (1) IN2014DN10734A (https=)
MX (2) MX369768B (https=)
NZ (1) NZ702369A (https=)
SG (1) SG11201407880QA (https=)
WO (1) WO2013181639A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
MX369768B (es) * 2012-06-01 2019-11-21 Berg Llc Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer.
SG10201903112WA (en) * 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
US9996463B2 (en) * 2015-11-10 2018-06-12 International Business Machines Corporation Selection and placement of volumes in a storage system using stripes
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20170255565A1 (en) * 2016-03-02 2017-09-07 Intel Corporation Method and apparatus for providing a contiguously addressable memory region by remapping an address space
US20200093751A1 (en) * 2016-06-28 2020-03-26 Der-Yang Tien Chemoprotective/chemoactive nanodroplets and methods of use thereof
DK3634391T3 (da) * 2017-05-17 2025-03-31 Bpgbio Inc Anvendelse af coenzym q10-formuleringer i behandlingen og forebyggelsen af epidermolysis bullosa
WO2023099436A1 (en) * 2021-12-01 2023-06-08 Gambro Lundia Ab New dialysis fluid
WO2025087731A1 (en) * 2023-10-24 2025-05-01 Gambro Lundia Ab Compositions comprising insulin and ketones bodies to treat cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
WO2005048925A2 (en) * 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
ES2809302T3 (es) * 2004-01-22 2021-03-03 Univ Miami Formulaciones de coenzima Q10 para tratar tumores sólidos mediante administración intravenosa
JPWO2008069276A1 (ja) * 2006-12-06 2010-03-25 株式会社カネカ 癌治療剤および発癌抑制剤
CA2680825C (en) 2007-03-22 2013-10-29 Cytotech Labs, Llc Topical formulations having enhanced bioavailability
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
AU2010247800A1 (en) * 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
GB0913193D0 (en) 2009-07-29 2009-09-02 Johnson Matthey Plc Deoxygenation process
CN105168135A (zh) * 2010-03-12 2015-12-23 博格有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
MX369768B (es) * 2012-06-01 2019-11-21 Berg Llc Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer.

Also Published As

Publication number Publication date
ES2761449T3 (es) 2020-05-19
MX369768B (es) 2019-11-21
EP2854528B1 (en) 2019-09-18
JP6352905B2 (ja) 2018-07-04
IL236008A0 (en) 2015-02-01
WO2013181639A8 (en) 2014-12-31
HK1208995A1 (en) 2016-03-24
CN104507308A (zh) 2015-04-08
JP2018168164A (ja) 2018-11-01
JP2020183440A (ja) 2020-11-12
KR20150022932A (ko) 2015-03-04
KR102163948B1 (ko) 2020-10-12
IL236008B (en) 2018-08-30
US20220096399A1 (en) 2022-03-31
WO2013181639A1 (en) 2013-12-05
MX2019013776A (es) 2020-01-30
EP2854528A1 (en) 2015-04-08
EA201492187A1 (ru) 2015-05-29
AU2017202567A1 (en) 2017-05-11
US20170216223A1 (en) 2017-08-03
EP2854528A4 (en) 2016-03-09
BR112014029954A2 (pt) 2017-06-27
US20140017317A1 (en) 2014-01-16
EA032345B1 (ru) 2019-05-31
SG11201407880QA (en) 2014-12-30
JP7225167B2 (ja) 2023-02-20
AU2017202567B2 (en) 2019-06-13
EP2854528B8 (en) 2019-10-23
CA2875150C (en) 2020-10-27
CA2875150A1 (en) 2013-12-05
NZ702369A (en) 2016-12-23
CA3090268A1 (en) 2013-12-05
MX2014014492A (es) 2015-05-12
JP2015518056A (ja) 2015-06-25
IN2014DN10734A (https=) 2015-09-04
AU2013267166A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
KR102163948B1 (ko) 조효소 q10을 이용한 고형 종양의 치료
JP6974369B2 (ja) コエンザイムｑ１０併用療法を用いた癌の処置方法
AU2017206279B2 (en) Methods of treating central nervous system tumors
US20200330400A1 (en) Methods for the treatment of cancer using coenzyme q10 and fatty acid metabolism inhibitors
KR20160048210A (ko) 코엔자임 q10의 연속주입에 의한 암치료 방법
WO2017087576A1 (en) Methods of treatment of temozolomide-resistant glioma using coenzyme q10
HK1208995B (en) Treatment of solid tumors using coenzyme q10

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20201005

Application number text: 1020147037100

Filing date: 20141231

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201103

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201201

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210901

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201201

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I